, where the targeted delivery system effectively suppressed tumor growth in a human B-NHL xenograft model. This targeted delivery strategy offers a precision approach to gene silencing in hematologic malignancies, potentially improving therapeutic efficacy and reducing adverse effects compared to current non-selective treatments for hematological malignancies, including B-NHL and CLL.
No takes yet. Share an insight, caveat, or question.
Puthenveetil et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: